BACKGROUND: Plasma brain natriuretic peptide (BNP) is used as a marker of congestive heart failure. Moreover, plasma BNP levels are increased in patients with acute ischemic stroke, in particular, cardioembolic stroke. We investigated whether the plasma BNP level can also be used as a biological marker to differentiate specific stroke subtype, in particular cardioembolic stroke from the other ischemic stroke subtypes. METHODS: Consecutive patients (total 200; 124 males, 76 females; mean age, 71.4 years) with acute ischemic stroke within 24 hours of onset were prospectively enrolled. We measured plasma BNP on admission. Patients were divided into four groups according to the TOAST classification: large-vessel disease (LVD), cardioembolism (CE), small-vessel disease (SVD), and other stroke. Correlation between plasma BNP level and stroke subtype was then examined. RESULTS: Cardioembolism (41%) was the most frequent stroke subtype, followed by other stroke (34%), SVD (16%), and LVD (9%). Age, female, atrial fibrillation, NIHSS score > or = 7 on admission and mRS score > or = 3 at discharge were significantly higher in CE than in the other stroke subtypes. The mean plasma BNP level of the CE group was significantly higher than that of the other 3 subtypes (409.6 pg/mL for CE, 94.0 pg/mL for LVD, 37.4 pg/mL for SVD, and 156.9 pg/mL for others, p<0.001). The optimal cut-off concentration, sensitivity, and specificity of plasma BNP levels to distinguish CE from other stroke subtypes were 140.0 pg/mL, 80.5% and 80.5%, respectively. CONCLUSION: Plasma BNP level is significantly higher in CE patients than in other stroke subtypes, and thus physicians should strongly consider CE when the plasma BNP level is over 140.0 pg/mL in patients with acute ischemic stroke.
BACKGROUND: Plasma brain natriuretic peptide (BNP) is used as a marker of congestive heart failure. Moreover, plasma BNP levels are increased in patients with acute ischemic stroke, in particular, cardioembolic stroke. We investigated whether the plasma BNP level can also be used as a biological marker to differentiate specific stroke subtype, in particular cardioembolic stroke from the other ischemic stroke subtypes. METHODS: Consecutive patients (total 200; 124 males, 76 females; mean age, 71.4 years) with acute ischemic stroke within 24 hours of onset were prospectively enrolled. We measured plasma BNP on admission. Patients were divided into four groups according to the TOAST classification: large-vessel disease (LVD), cardioembolism (CE), small-vessel disease (SVD), and other stroke. Correlation between plasma BNP level and stroke subtype was then examined. RESULTS: Cardioembolism (41%) was the most frequent stroke subtype, followed by other stroke (34%), SVD (16%), and LVD (9%). Age, female, atrial fibrillation, NIHSS score > or = 7 on admission and mRS score > or = 3 at discharge were significantly higher in CE than in the other stroke subtypes. The mean plasma BNP level of the CE group was significantly higher than that of the other 3 subtypes (409.6 pg/mL for CE, 94.0 pg/mL for LVD, 37.4 pg/mL for SVD, and 156.9 pg/mL for others, p<0.001). The optimal cut-off concentration, sensitivity, and specificity of plasma BNP levels to distinguish CE from other stroke subtypes were 140.0 pg/mL, 80.5% and 80.5%, respectively. CONCLUSION: Plasma BNP level is significantly higher in CE patients than in other stroke subtypes, and thus physicians should strongly consider CE when the plasma BNP level is over 140.0 pg/mL in patients with acute ischemic stroke.
Authors: E Santamarina; A Penalba; T García-Berrocoso; P Delgado; M Quintana; T González-Alujas; M Ribó; O Maisterra; C A Molina; A Evangelista; J Alvarez-Sabín; J Montaner Journal: J Neurol Date: 2012-05-17 Impact factor: 4.849
Authors: Glen C Jickling; Huichun Xu; Boryana Stamova; Bradley P Ander; Xinhua Zhan; Yingfang Tian; Dazhi Liu; Renée J Turner; Matthew Mesias; Piero Verro; Jane Khoury; Edward C Jauch; Arthur Pancioli; Joseph P Broderick; Frank R Sharp Journal: Ann Neurol Date: 2010-11 Impact factor: 10.422
Authors: Aleksandra Pikula; Alexa S Beiser; Charles DeCarli; Jayandra J Himali; Stephanie Debette; Rhoda Au; Jacob Selhub; Geoffrey H Toffler; Thomas J Wang; James B Meigs; Margaret Kelly-Hayes; Carlos S Kase; Philip A Wolf; Ramachandran S Vasan; Sudha Seshadri Journal: Circulation Date: 2012-03-28 Impact factor: 29.690
Authors: Pam R Taub; Jeremy D Fields; Alan H B Wu; Jacob C Miss; Michael T Lawton; Wade S Smith; William L Young; Jonathan G Zaroff; Nerissa U Ko Journal: Neurocrit Care Date: 2011-08 Impact factor: 3.210
Authors: W T Longstreth; Richard A Kronmal; John L P Thompson; Robert H Christenson; Steven R Levine; Rebecca Gross; Robin L Brey; Richard Buchsbaum; Mitchell S V Elkind; David L Tirschwell; Stephen L Seliger; J P Mohr; Christopher R deFilippi Journal: Stroke Date: 2013-01-22 Impact factor: 7.914
Authors: William T Hu; David M Holtzman; Anne M Fagan; Leslie M Shaw; Richard Perrin; Steven E Arnold; Murray Grossman; Chengjie Xiong; Rebecca Craig-Schapiro; Christopher M Clark; Eve Pickering; Max Kuhn; Yu Chen; Vivianna M Van Deerlin; Leo McCluskey; Lauren Elman; Jason Karlawish; Alice Chen-Plotkin; Howard I Hurtig; Andrew Siderowf; Frank Swenson; Virginia M-Y Lee; John C Morris; John Q Trojanowski; Holly Soares Journal: Neurology Date: 2012-08-01 Impact factor: 9.910
Authors: Henrik Reinhard; Ellen Garde; Arnold Skimminge; Per Åkeson; Thomas Zoëga Ramsøy; Kaj Winther; Hans-Henrik Parving; Peter Rossing; Peter K Jacobsen Journal: Cardiovasc Diabetol Date: 2012-10-03 Impact factor: 9.951
Authors: Seo Hyun Kim; Ji-Yong Lee; Sang Hyun Park; Hyun-Chan Jang; Eun Ju Lim; Sei-Jin Chang; Sung-Soo Lee Journal: Int J Med Sci Date: 2012-12-27 Impact factor: 3.738